Bromfed: Dosing, Contraindications, and Safety Considerations
Bromfed (brompheniramine/phenylephrine) is an effective first-generation antihistamine-decongestant combination for treating upper respiratory symptoms, particularly in the common cold, but requires careful attention to contraindications and age-appropriate dosing.
Mechanism and Clinical Use
Bromfed combines brompheniramine maleate (an H1-receptor antagonist) with phenylephrine (an α-sympathetic agonist decongestant). Brompheniramine provides antihistaminic and anticholinergic effects with peak plasma concentrations at 3-5 hours and a terminal half-life of approximately 12 hours 1. Phenylephrine produces nasal vasoconstriction with onset within 30 minutes 1.
For acute cough with postnasal drip and throat clearing associated with the common cold, first-generation antihistamine/decongestant preparations like brompheniramine with pseudoephedrine (a related decongestant) are recommended 2. This represents Grade A evidence for symptomatic relief.
Dosing Guidelines
Adults
- Standard dose: Brompheniramine 12 mg twice daily (extended-release formulation) 1
- Lower doses (8 mg twice daily) may be considered but provide less symptom relief 3, 4
Pediatric Dosing
Bromfed is contraindicated in infants under 6 months 1. For children ≥6 months:
- Ages 2-5 years: 1-2 mg brompheniramine per dose
- Ages 6-11 years: 2-4 mg brompheniramine per dose
- Ages 12-17 years: 4 mg brompheniramine per dose 5
Phenylephrine dosing ranges from 2.5-10 mg using modified weight-age schedules 6. Pediatric pharmacokinetic studies demonstrate that age/weight-based dosing achieves consistent plasma concentrations across age groups 5.
Absolute Contraindications
Do not use Bromfed in patients with:
- MAO inhibitor use (current or within 14 days): Risk of hyperpyrexia, hypotension, and death from drug interactions 1
- Nursing mothers: Higher risk of antihistamine intolerance in infants, particularly newborns and prematures 1
- Infants <6 months: Safety not established 1
- Narrow-angle glaucoma: Anticholinergic effects can precipitate acute angle closure 1
Use With Extreme Caution
Cardiovascular Conditions
- Hypertension, heart disease, coronary artery disease: Phenylephrine's vasoconstrictive effects can elevate blood pressure 1, 7
- Aneurysms: Risk of rupture with sympathomimetic-induced hypertension 7
- Advanced arteriosclerosis: Increased cardiovascular event risk 7
Respiratory Conditions
- Bronchial asthma: Anticholinergic effects may worsen bronchospasm 1
Other High-Risk Conditions
- Diabetes mellitus (especially long-standing insulin-dependent): Sympathomimetic effects on glucose metabolism 1, 7
- Thyroid disease: Potentiation of sympathomimetic effects 1
- Gastrointestinal obstruction: Anticholinergic effects reduce motility 1
- Urinary bladder neck obstruction/prostatic hypertrophy: Anticholinergic effects worsen urinary retention 1
Critical Drug Interactions
MAO Inhibitors
Absolutely contraindicated combination. MAO inhibitors:
- Prolong and intensify anticholinergic effects
- Enhance pseudoephedrine/phenylephrine effects
- Can cause life-threatening hypertensive crisis 1
CNS Depressants
Brompheniramine has additive sedative effects with:
- Alcohol
- Benzodiazepines
- Opioids
- Sedative-hypnotics
- Antianxiety agents 1
Antihypertensive Medications
Phenylephrine may reduce effectiveness of blood pressure medications, requiring dose adjustments 1.
Safety Monitoring and Adverse Effects
Common Adverse Effects
- Somnolence: Most frequent with brompheniramine, particularly in younger children (ages 2-5) 5
- CNS effects: Sedation, paradoxical excitement/agitation (especially in children) 1
- Anticholinergic effects: Dry mouth, urinary retention, constipation
Serious Concerns
Phenylephrine can cause severe cardiovascular effects including:
- Elevated blood pressure
- Stroke (rare but documented) 7
- Reflex bradycardia (though studies show this is uncommon in practice) 8
Patient Counseling
Warn patients explicitly about:
- Avoiding activities requiring mental alertness (driving, operating machinery) until individual response is known 1
- Not combining with alcohol or other sedating medications
- Reporting cardiovascular symptoms (chest pain, palpitations, severe headache)
Clinical Efficacy Considerations
Brompheniramine 12 mg twice daily demonstrates superior efficacy compared to:
- Second-generation antihistamines (terfenadine, loratadine) for allergic rhinitis symptoms 3, 4, 9
- Placebo for total symptom relief and nasal symptom clusters 4
However, newer nonsedating antihistamines are ineffective for common cold-related cough and should not be used 2.
Special Populations
Elderly
Use lower initial doses due to increased sensitivity to anticholinergic and sympathomimetic effects. Monitor closely for urinary retention, confusion, and cardiovascular effects 7.
Pregnancy
Category C: Use only if clearly needed. Animal studies show no evidence of harm, but human data are lacking 1.
Common Pitfalls to Avoid
- Do not prescribe to patients on MAO inhibitors - this is the most dangerous interaction
- Do not assume second-generation antihistamines are equivalent - they lack efficacy for common cold symptoms
- Do not overlook cardiovascular risk factors - even "healthy" patients with undiagnosed hypertension are at risk
- Do not use in nursing mothers - risk to infant outweighs benefits
- Do not combine with multiple CNS depressants without careful monitoring